Jianmin Pharmaceutical Group Co.,Ltd. (SHA:600976)

SHA:600976 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Jan 1, 2021
Cash & Equivalents	272.04	163.17	305.12	219.33	301.66	91.17
Trading Asset Securities	931.89	954.19	694.46	641.38	538.63	485.79
Cash & Short-Term Investments	1,204	1,117	999.58	860.71	840.28	576.96
Cash Growth	27.65%	11.78%	16.13%	2.43%	45.64%	21.10%
Accounts Receivable	1,014	957.56	1,150	868.66	674.6	586.18
Other Receivables	29.47	25.76	31.43	49.64	21.43	8.98
Receivables	1,044	983.33	1,181	918.29	696.03	595.17
Inventory	306.18	354.31	450.85	362.88	222.6	229
Other Current Assets	109.62	146.43	134.06	162.85	104.5	111.96
Total Current Assets	2,664	2,601	2,766	2,305	1,863	1,513
Property, Plant & Equipment	617.47	595.59	450.7	417.65	396.65	371.76
Long-Term Investments	689.69	772.18	650.42	444.94	326.85	318.86
Goodwill	0.21	0.21	0.21	0.21	0.21	0.21
Other Intangible Assets	27.38	28.19	28.87	31.16	32.98	22.16
Long-Term Deferred Tax Assets	129.49	129.49	139.44	117.27	118.33	85.23
Long-Term Deferred Charges	127.7	130.78	111.27	91.66	87.64	98.38
Other Long-Term Assets	22.19	19.74	21.14	32.56	30.01	7.65
Total Assets	4,278	4,278	4,168	3,440	2,856	2,417
Accounts Payable	660.83	742.22	782.91	611.06	374.92	375.86
Accrued Expenses	32	574.78	724.73	620.32	592.57	486.13
Short-Term Debt	105	140.9	79.45	22.52	45	20
Current Portion of Leases	3.56	6.39	5.12	7.34	6.1	0.08
Current Income Taxes Payable	69.37	52.74	66.23	49.68	71.75	54.36
Current Unearned Revenue	29.87	61.43	41.19	82.52	37.04	41.68
Other Current Liabilities	717.96	166.66	157.31	140.25	191.85	89.63
Total Current Liabilities	1,619	1,745	1,857	1,534	1,319	1,068
Long-Term Debt	12.1	4	-	-	-	-
Long-Term Leases	32.91	24.43	30.29	23.48	20.37	0.08
Long-Term Unearned Revenue	46.52	46.55	18.61	12.18	27.72	25.44
Long-Term Deferred Tax Liabilities	7.2	7.2	5.62	5.97	0.84	0.82
Total Liabilities	1,717	1,827	1,911	1,575	1,368	1,094
Common Stock	153.4	153.4	153.4	153.4	153.4	153.4
Additional Paid-In Capital	523.42	523.42	520.68	509.17	421.5	301.46
Retained Earnings	1,869	1,758	1,580	1,212	931.06	863.71
Treasury Stock	-	-	-6.76	-14.99	-25.08	-1.66
Total Common Equity	2,545	2,435	2,248	1,860	1,481	1,317
Minority Interest	14.9	15.03	8.78	4.99	7.04	6.35
Shareholders' Equity	2,560	2,450	2,256	1,865	1,488	1,323
Total Liabilities & Equity	4,278	4,278	4,168	3,440	2,856	2,417
Total Debt	153.56	175.71	114.86	53.34	71.48	20.16
Net Cash (Debt)	1,050	941.65	884.72	807.37	768.81	556.8
Net Cash Growth	27.43%	6.44%	9.58%	5.02%	38.07%	16.87%
Net Cash Per Share	6.93	6.19	5.79	5.30	5.06	3.62
Filing Date Shares Outstanding	153.4	153.4	153.82	152.78	151.97	151.97
Total Common Shares Outstanding	153.4	153.4	153.82	152.78	151.97	153.32
Working Capital	1,045	856.33	908.95	771.06	544.18	445.34
Book Value Per Share	16.59	15.88	14.61	12.17	9.74	8.59
Tangible Book Value	2,518	2,407	2,219	1,829	1,448	1,295
Tangible Book Value Per Share	16.41	15.69	14.42	11.97	9.53	8.44
Buildings	-	287.12	284.12	289.38	298.05	342
Machinery	-	314.22	312.36	301.9	251.25	173.95
Construction In Progress	-	206.68	41.48	17.19	16.73	43.32

Source: S&P Global Market Intelligence. Standard template. Financial Sources.